Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
Long non-coding RNAs (lncRNAs) are emerging as regulators in cancer development and progression, and aberrant lncRNA profiles have been reported in several cancers. Here, we evaluated the potential of using the maternally expressed gene 3 (MEG3) tissue level as a prognostic marker in high-grade sero...
Main Authors: | Marianna Buttarelli, Marta De Donato, Giuseppina Raspaglio, Gabriele Babini, Alessandra Ciucci, Enrica Martinelli, Pina Baccaro, Tina Pasciuto, Anna Fagotti, Giovanni Scambia, Daniela Gallo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/966 |
Similar Items
-
Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
by: Giuseppina Raspaglio, et al.
Published: (2023-04-01) -
The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)
by: Elahe Seyed Hosseini, et al.
Published: (2021-08-01) -
The lncRNA MEG3 downregulation leads to osteoarthritis progression via miR-16/SMAD7 axis
by: Jin Xu, et al.
Published: (2017-12-01) -
Immune-Related Gene Expression Analysis Revealed Three lncRNAs as Prognostic Factors for Colon Cancer
by: Xiao-Liang Xing, et al.
Published: (2021-07-01) -
Immune-Related lncRNAs to Construct Novel Signatures and Predict the Prognosis of Rectal Cancer
by: Xiao-Liang Xing, et al.
Published: (2021-08-01)